• Avillion will finance 100% of the regulatory
    approval study.
  • Avillion will contract with and manage suitable CROs, selected by Pharma (or selected jointly by Avillion

    and Pharma).
  • Joint steering and development committees will be established as governance mechanisms to develop a strategy (or to plan) and manage ongoing clinical and regulatory activities.
  • Pharma will maintain absolute ownership of and control on commercialising the asset.